Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
03 août 2023 16h30 HE
|
Cellectis Inc.
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22),...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
03 août 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Monthly information on share capital and company voting rights
01 août 2023 16h30 HE
|
Cellectis Inc.
PARIS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
19 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
18 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
12 juil. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Mustang Bio Announces Participation in Upcoming Scientific Meetings
06 juil. 2023 08h00 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
06 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Monthly information on share capital and company voting rights
05 juil. 2023 16h30 HE
|
Cellectis Inc.
PARIS, July 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
28 juin 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...